DekaBank Deutsche Girozentrale’s Ultragenyx Pharmaceutical RARE Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.1M	Hold	57,000	–	–	﹤0.01%	773
2026 Q1	$1.12M	Hold	57,000	–	–	﹤0.01%	773
2025 Q4	$2.9M	Hold	57,000	–	–	0.01%	684
2025 Q3	$1.73M	Hold	57,000	–	–	﹤0.01%	776
2025 Q2	$2.09M	Hold	57,000	–	–	﹤0.01%	736
2025 Q1	$2.13M	Hold	57,000	–	–	﹤0.01%	720
2024 Q4	$2.45M	Hold	57,000	–	–	﹤0.01%	706
2024 Q3	$3.09M	Hold	57,000	–	–	0.01%	677
2024 Q2	$2.36M	Hold	57,000	–	–	﹤0.01%	733
2024 Q1	$2.66M	Hold	57,000	–	–	0.01%	702
2023 Q4	$2.75M	Buy	57,000 +17,000	+43%	+$659K	0.01%	711
2023 Q3	$1.41M	Hold	40,000	–	–	﹤0.01%	814
2023 Q2	$1.87M	Buy	40,000 +10,000	+33%	+$464K	﹤0.01%	763
2023 Q1	$1.15M	Hold	30,000	–	–	﹤0.01%	839
2022 Q4	$1.35M	Hold	30,000	–	–	﹤0.01%	811
2022 Q3	$1.21M	Sell	30,000 -10,360	-26%	-$532K	﹤0.01%	825
2022 Q2	$2.4M	Sell	40,360 -1,000	-2%	-$61.5K	0.01%	685
2022 Q1	$2.95M	Hold	41,360	–	–	0.01%	673
2021 Q4	$3.42M	Buy	41,360 +6,450	+18%	+$525K	0.01%	654
2021 Q3	$3.01M	Buy	34,910 +18,000	+106%	+$1.63M	0.01%	642
2021 Q2	$1.62M	Hold	16,910	–	–	﹤0.01%	777
2021 Q1	$1.9M	Hold	16,910	–	–	0.01%	709
2020 Q4	$2.48M	Sell	16,910 -1,540	-8%	-$183K	0.01%	620
2020 Q3	$1.56M	Buy	+18,450	New	+$1.53M	0.01%	644
2019 Q4	–	Sell	-25,250	Closed	-$1.07M	–	1207
2019 Q3	$1.07M	Sell	25,250 -57,750	-70%	-$3.14M	0.01%	654
2019 Q2	$5.15M	Buy	+83,000	New	+$5.28M	0.03%	418
2019 Q1	–	Sell	-20,000	Closed	-$840K	–	1245
2018 Q4	$840K	Buy	+20,000	New	+$1.09M	0.01%	726
2018 Q2	–	Sell	-40,920	Closed	-$2.06M	–	1238
2018 Q1	$2.06M	Buy	40,920 +17,600	+75%	+$886K	0.01%	564
2017 Q4	$1.43M	Hold	23,320	–	–	0.01%	617
2017 Q3	$1.43M	Hold	23,320	–	–	0.01%	625
2017 Q2	$1.44M	Hold	23,320	–	–	0.01%	617
2017 Q1	$1.57M	Sell	23,320 -4,500	-16%	-$343K	0.01%	531
2016 Q4	$1.98M	Sell	27,820 -6,900	-20%	-$490K	0.02%	447
2016 Q3	$2.38M	Sell	34,720 -25,000	-42%	-$1.6M	0.03%	427
2016 Q2	$2.97M	Buy	59,720 +41,200	+222%	+$2.67M	0.03%	395
2016 Q1	$1.06M	Sell	18,520 -1,150	-6%	-$75.2K	0.01%	538
2015 Q4	$2.22M	Buy	19,670 +1,610	+9%	+$161K	0.03%	443
2015 Q3	$1.74M	Buy	18,060 +1,060	+6%	+$121K	0.02%	467
2015 Q2	$1.74M	Buy	17,000 +600	+4%	+$46.6K	0.02%	472
2015 Q1	$1.02M	Buy	+16,400	New	+$911K	0.01%	571

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EHI

Eagle Health Investments Greenwich, Connecticut $603M AUM 111.06% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

DekaBank Deutsche Girozentrale's RARE Position: Q2 2026 in Review

DekaBank Deutsche Girozentrale held its Ultragenyx Pharmaceutical (RARE) position steady in Q2 2026 at 57,000 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #773.

DekaBank Deutsche Girozentrale first reported a position in RARE in Q1 2015 and has held it in 40 quarters since. The position peaked at $5.15M in Q2 2019. 108 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

DekaBank Deutsche Girozentrale held 57,000 shares of Ultragenyx Pharmaceutical worth $1.1M as of Q2 2026.
DekaBank Deutsche Girozentrale left its Ultragenyx Pharmaceutical share count unchanged in Q2 2026.
Ultragenyx Pharmaceutical made up ﹤0.01% of DekaBank Deutsche Girozentrale's portfolio in Q2 2026, its #773 holding.
DekaBank Deutsche Girozentrale first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 40 quarters since.
DekaBank Deutsche Girozentrale's Ultragenyx Pharmaceutical position peaked at $5.15M in Q2 2019.
108 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2026, filed 5 Aug 2026.